Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 7/20 | 0.33 |
| ▸ | DRD3 | P35462 | 7/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124383 | 0.97 | DRD2 (0.34) | KDM4ELMNADRD2DRD3ADRA1A | |
| SCHEMBL7126008 | 0.94 | HTR1A (0.36) | KDM4ELMNADRD2DRD3ADRA1A | |
| SCHEMBL7126212 | 0.94 | DRD2 (0.32) | LMNADRD2DRD3 | |
| SCHEMBL7128484 | 0.90 | KDM4E (0.35) | KDM4ELMNADRD2DRD3ADRA1A | |
| SCHEMBL7125225 | 0.89 | ADRA1B (0.32) | KDM4EADRA1BHTR1AKCNH2ALDH1A1 | |
| SCHEMBL7124367 | 0.88 | GRM2 (0.40) | KDM4ELMNADRD2DRD3DRD4 | |
| SCHEMBL7128124 | 0.87 | KDM4E (0.34) | KDM4ELMNADRD2DRD3ADRA1A | |
| SCHEMBL7129896 | 0.87 | HTR1A (0.35) | KDM4ELMNADRD2DRD3ADRA1A | |
| SCHEMBL7123088 | 0.86 | THRB (0.36) | KDM4ELMNADRD2DRD3HTR1A | |
| SCHEMBL7124335 | 0.85 | CYP1A2 (0.45) | KDM4EDRD2DRD3ADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050306-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-03-13 | — | — | US | claimed |
| EP-1246820-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2002-10-09 | — | — | EP | claimed |
| WO-2001049683-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | claimed |
| US-20030050306-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-03-13 | — | — | US | disclosed |
| EP-1246820-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001049683-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050306-A1 | Novel heteroaryl derivatives, their preparation and use | CRBN, CDR2, DRD3 | KDM4E 2331/4885LMNA 2521/4885DRD2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.